Statin therapy cost-effectively improves health outcomes for ≥70s
By
HealthDay News
Sep 12, 2024
The lifetime use of a standard statin increased quality-adjusted life years by 0.24 to 0.70, with further increase seen for higher-intensity statins.
Semaglutide reduces risk for MACE in patients with obesity and heart failure
By
Haymarket Media
Aug 28, 2024
MACE, heart failure composite end point, cardiovascular death and all-cause death all improved with semaglutide for patients with versus without heart failure.
PREVENT equations reclassify half of US adults to lower ASCVD risk
Aug 02, 2024
A considerable decrease was estimated in US adults receiving or recommended for preventive treatment with statins and antihypertensives.
Study: Professional medication review is a must when older adults want to scale back meds
By
Kristen Fischer
Jul 29, 2024
Many older adults want to cut back on taking multiple medications, or polypharmacy, but they need to talk to a clinician or pharmacist first, authors of a new report say.
Active commuters have lower risks for morbidity, mortality
Jul 17, 2024
Researchers examined prospective associations with multiple health outcomes over 18 years for pedestrians and cyclists using data for 82,297 individuals aged 16 to 74 years.
Mental health treatment linked to better outcomes in CAD, heart failure
Mar 22, 2024
Patients receiving mental health treatment were less likely to be rehospitalized, have an emergency department visit or die from any cause.
Medicare to cover Wegovy when patients also have heart disease
Mar 22, 2024
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Semaglutide boosts kidney outcomes with obesity + cardiovascular disease
May 28, 2024
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.